Zum Inhalt wechseln


Duopharma started its activities as a pharmaceutical trading company by importing and marketing pharmaceuticals to the medical profession in Malaysia.
1986 Duopharma started its manufacturing activity by producing its first product, Pontacid Capsule.
1993 Duopharma started the construction of the new factory to meet the additional requirements of oral preparation and embark in the field of injectables.
1995 The oral preparation production moved to the new factory, located in Klang.
1996 Duopharma was granted regulatory approval from the Malaysian National Pharmaceutical Control Bureau for production of Haemodialysis solution, sophisticated production of injectables, sterile eye drop preparations, sterile antibiotic injectables in the form of powder, dental cartridges and Large Volume Infusion. The production was started in stages. In the year 2001, Duopharma became the first Malaysian Company to manufacture dental cartridges.
1997 Duopharma commenced production of Large Volume Infusion.
2000 An additional new manufacturing facility was built based on regulatory requirement from PIC, which is the European Commission and the Malaysian National Pharmaceutical Control Bureau.
2001 Duopharma become the first Malaysian company to manufacture dental cartridges, Denkah.
2002 Apart from manufacturing pharmaceuticals in the form of tablets, capsules, injectables, haemodialysis and irrigation solution, the Company is now working on Biotech injectables, where R&D and stability studies of different formulations are being carried out.
2004 Duopharma was granted regulatory approval from Ministry of Health for the production of small volume injectables in new factory.
2005 Tekan Maju Sdn Bhd, a wholly-owned subsidiary of Chemical Company of Malaysia Berhad, acquired 36% of the issued and paid-up share capital of Duopharma, at RM2.80 per Duopharma share for a total cash consideration of RM134, 216, 292.
2006 Launch of Diamelon, a new OTC product to promote overall wellness to help control blood glucose levels.
2006 Duopharma Biotech rebranded to CCM Duopharma Biotech.
2007 Launch of Donna Forte 500mg as an extension of Donna 250mg to treat the symptoms of osteoarthritis.
2009 Signing of sole and exclusive distributorship for Belupo's products in the ASEAN market and Belupo for the sole and exclusive distributorship for CCM's products for the Central and Eastern Europe and the Russian markets.
2009 MOU signing with Inno Bio Ventures to jointly develop biosimilar products and explore future business opportunities, especially in the manufacturing and commercialisation of erythropoietin (EPO) biosimilars.

Established first Non-Live cell vaccines Fill & Finish facility in South East Asia

2012 Strategic Collaboration with PanGen Biotech Inc. to pioneer development of biosimilars for kidney failure treatment in Malaysia

Launch of the historical Phase III Clinical trials for the treatment of kidney failure in Malaysia

Last updated : 23 Feb 2018

© Copyright 2018 CCM Duopharma Biotech Berhad. All Rights Reserved.